RxDoctor Payments Data

Fei Lee, APRN

Family · Memphis, TNNPI 1871905174

Payments from drug & device makers

$1,314in general payments, 2019–2025

Across 47 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$805
  • Boehringer Ingelheim$173
  • Esperion Therapeutics, Inc.$78
  • Lilly USA, LLC$48
  • AbbVie$37
  • RGH Enterprises LLC$35
  • plus $138 from 6 others

What the payments were for

  • Food & beverage$1,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$53,867
Medicare patients
159
Services billed
1,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$44,554
JardianceEmpagliflozin25$26,016
FarxigaDapagliflozin Propanediol14$21,065
EliquisApixaban14$12,050
Rosuvastatin Calcium111$2,333
Ezetimibe35$1,191
Atorvastatin Calcium105$1,073
Potassium Chloride54$1,071
Olmesartan Medoxomil23$1,012
Duloxetine Hcl43$690
Azelastine Hcl23$670
Amlodipine Besylate153$665
Nebivolol Hcl13$655
Losartan Potassium63$607
Omeprazole46$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$805$44,55432 claims
Boehringer IngelheimJardiance$173$26,01625 claims
AstraZenecaFarxiga$16$21,06514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →